Category: PRESS RELEASES

28
May 2026
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
Read more
12
May 2026
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
Read more
29
January 2026
Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
Read more
09
December 2025
Enterome presents strengthened interim Phase 2 results for lead OncoMimics™ immunotherapy EO2463 to treat follicular lymphoma at ASH
Read more
02
December 2025
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
Read more
13
November 2025
Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting
Read more
16
October 2025
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
Read more
23
June 2025
The widely read BioWorld biopharmaceutical daily took a comprehensive look at Enterome’s work after the success of our $19 million funding round to advance the EO2463 non-Hodgkin lymphoma therapy.
Read more
23
June 2025
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
Read more

Enterome

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Email: info@enterome.com
Metro Station: Ledru-Rollin (Line 8)